Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years.

Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years.

OBJECTIVE: Epidemiological studies have shown an increased risk for prostate carcinoma in men with serum IGF-I in the upper part of the age-related reference range. Recombinant human GH (rhGH) is widely used in patients with GH deficiency, usually raising the serum IGF-I levels into the normal range...

Full description

Bibliographic Details
Main Authors:	le Roux, C, Jenkins, P, Chew, S, Camacho-Hübner, C, Grossman, AB, Besser, G, Monson, J
Format:	Journal article
Language:	English
Published:	2002

Similar Items

Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
by: Drake, WM, et al.
Published: (1998)

Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients.
by: Agha, A, et al.
Published: (2007)

Role of fasting plasma glucose, glycated haemoglobin and homeostatic model assessment in the detection of glucose intolerance in adult hypopituitary patients during growth hormone replacement therapy.
by: Colson, A, et al.
Published: (2008)

Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.
by: Florakis, D, et al.
Published: (2000)

Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.
by: Chung, T, et al.
Published: (2008)

Comments on 'Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two-year study' by Florakis et al (2000) - Reply
by: Monson, J, et al.
Published: (2001)

Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy.
by: Frajese, G, et al.
Published: (2001)

The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
by: Irene K Oglesby, et al.
Published: (2023-09-01)

The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults.
by: Sverrisdóttir, Y, et al.
Published: (2003)

Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement.
by: Chung, T, et al.
Published: (2005)

Growth hormone deficiency and replacement in patients with treated Cushing's Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density.
by: Colson, A, et al.
Published: (2006)

Classic cardiovascular risk factors improve in very elderly hypopituitary patients treated on standard hormone replacement in long term follow- up
by: Isabella Naves Rosa, et al.
Published: (2021-03-01)

Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
by: Kaltsas, G, et al.
Published: (2001)

Circulating Levels of Irisin in Hypopituitary and Normal Subjects.
by: Lara Pena-Bello, et al.
Published: (2016-01-01)

Insulin-like growth factor-I and- II in combination inhibit the release of growth hormone-releasing hormone from the rat hypothalamus in vitro.
by: Korbonits, M, et al.
Published: (1996)

Prevalence and risk factors of the metabolic syndrome in young adults with childhood-onset hypopituitary growth hormone deficiency
by: Han Hyuk Lim, et al.
Published: (2010-10-01)

A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.
by: Miraki-Moud, F, et al.
Published: (2005)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
by: Jenkins, P, et al.
Published: (2000)

Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly.
by: Jenkins, P, et al.
Published: (2000)

Male-female differences in 6-sulfatoxymelatonin excretion in hypopituitary patients
by: Hugo L. Fideleff, et al.
Published: (2016-02-01)

Growth hormone cut-off post glucagon stimulation test in an Indian cohort of overweight/obese hypopituitary patients for the diagnosis of adult growth hormone deficiency
by: Vijay Sheker Reddy Danda, et al.
Published: (2023-01-01)

Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group.
by: Tomlinson, J, et al.
Published: (2001)

Racial differences in hypogonadal improvement and prostate-specific antigen levels in hypogonadal men treated with testosterone replacement therapy
by: Robert M. Coward, et al.
Published: (2010-12-01)

Successful treatment of childhood-onset Cushing's disease is associated with persistent reduction in growth hormone secretion.
by: Carroll, P, et al.
Published: (2004)

Growth hormone releasing hormone.
by: Grossman, A, et al.
Published: (1986)

Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone.
by: Trainer, P, et al.
Published: (1992)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
by: Vickers, A, et al.
Published: (2010)

Increased levels of insulin-like growth factor binding protein-2 in sera and tumours from patients with colonic neoplasia with and without acromegaly.
by: Miraki-Moud, F, et al.
Published: (2001)

Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
by: Korbonits, M, et al.
Published: (1998)

The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men
by: Jeremy YC Teoh, et al.
Published: (2017-01-01)

Stilboestrol pretreatment of children with short stature does not affect the growth hormone response to growth hormone-releasing hormone.
by: Ross, R, et al.
Published: (1987)

CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing's syndrome.
by: Sohaib, SA, et al.
Published: (1999)

Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome.
by: Isidori, A, et al.
Published: (2003)

Calcium and calmodulin mediation of growth hormone-releasing hormone release from the rat hypothalamus in vitro.
by: Honegger, J, et al.
Published: (1991)

Value of Prostate-Specific Antigen and Prostate-Specific Antigen Density in Detection of Prostate Cancer in an Iranian Population of Men
by: Mahyar Ghafoori, et al.
Published: (2009-08-01)

The Effect of Ofloxacin on Prostate Specific Antigen Level in Men with High Antigen
by: SMR Rabbani
Published: (2022-07-01)

The role of prostate-specific antigen in the prediction of hormone-sensitive prostate cancer
by: A. A. Gritskevich, et al.
Published: (2015-12-01)

Serum prostate specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia
by: Ebenezer Abotsi, et al.
Published: (2022-12-01)

Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects.
by: Castro, R, et al.
Published: (1990)

The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women.
by: Kaltsas, G, et al.
Published: (2003)